{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.55","upperLimit":"24.58","value":"16.380"},{"groupId":"OG001","lowerLimit":"8.45","upperLimit":"24.10","value":"16.240"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.","dispersionType":"Full Range","groups":[{"description":"Participants with Relapsed or Refractory Multiple Myeloma (RRMM) received belantamab mafodotin as 2.5 milligram (mg)/kilogram (kg) dose via intravenous (IV) infusion on Day 1 of every 21-day cycle (Q3W) maximum up to disease progression.","id":"OG000","title":"Main Study - Part 1: Belantamab Mafodotin 2.5 Milligram/ Kilogram (mg/kg)"},{"description":"Participants with RRMM received belantamab mafodotin as dose of 3.4 mg/kg via IV infusion on Day 1 of every 21-day cycle (Q3W) maximum up to disease progression.","id":"OG001","title":"Main Study - Part 1: Belantamab Mafodotin 3.4 mg/kg"}],"paramType":"MEDIAN","populationDescription":"Pharmacokinetic population.","reportingStatus":"POSTED","timeFrame":"Pre-Dose; EOI; 1 h, 3 h, 8 h and 24 h post-EOI, Day 8, Day 15 in Cycle 1; Pre-Dose on Cycle 2 Day 1","title":"Part 1: Tmax Following Single Dose Administration of Belantamab Mafodotin (Cys-mcMMAF)","type":"SECONDARY","unitOfMeasure":"hour (h)"}